ETF Managers Group’s AbCellera Biologics ABCL Stock Holding History

ETF Managers Group’s Portfolio ABCL Stock Details ABCL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	$713K	Buy	+94,496	New	+$858K	0.02%	326
2022 Q4	–	Sell	-84,143	Closed	-$832K	–	515
2022 Q3	$832K	Sell	84,143 -5,752	-6%	-$63.1K	0.03%	233
2022 Q2	$909K	Buy	89,895 +3,772	+4%	+$31.9K	0.03%	245
2022 Q1	$840K	Buy	86,123 +1,018	+1%	+$9.64K	0.02%	328
2021 Q4	$1.22M	Sell	85,105 -16,659	-16%	-$253K	0.02%	252
2021 Q3	$1.98M	Buy	101,764 +21,792	+27%	+$385K	0.04%	202
2021 Q2	$1.7M	Buy	79,972 +7,348	+10%	+$203K	0.03%	238
2021 Q1	$1.94M	Buy	+72,624	New	+$2.89M	0.03%	193

Other funds holding ABCL

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VOYA Investment Management Atlanta, Georgia $116B AUM 61.47% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

HMC

Harvard Management Company Boston, Massachusetts $4.26B AUM 5.81% 1-Year Est. Return

FFVM

Founders Fund VII Management San Francisco, California $2.03M AUM 72.34% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

ETF Managers Group's ABCL Position: Q1 2023 in Review

ETF Managers Group opened a new position in AbCellera Biologics (ABCL) in Q1 2023: 94,496 shares worth $713K. The stake represents 0.02% of the portfolio and ranks #326 among its holdings. This is a return to the name: ETF Managers Group previously reported a position in ABCL as recently as Q3 2022.

ETF Managers Group first reported a position in ABCL in Q1 2021 and has held it in 8 quarters since. The position peaked at $1.98M in Q3 2021. 183 funds tracked by Wall St. Rank hold ABCL as of Q1 2023.

ETF Managers Group held 94,496 shares of AbCellera Biologics worth $713K as of Q1 2023.
AbCellera Biologics was a new ETF Managers Group position in Q1 2023.
AbCellera Biologics made up 0.02% of ETF Managers Group's portfolio in Q1 2023, its #326 holding.
ETF Managers Group first reported a position in AbCellera Biologics in Q1 2021 and has held it in 8 quarters since.
ETF Managers Group's AbCellera Biologics position peaked at $1.98M in Q3 2021.
183 funds tracked by Wall St. Rank held AbCellera Biologics as of Q1 2023.

Based on ETF Managers Group's 13F filing for Q1 2023, filed 18 Apr 2023.